Skip to main content

Moderna shares tank after FDA delays COVID vaccine for 12- to 17-year-olds

Shares in Moderna Inc. dropped at least 5% as trading opened Monday after a delay in the decision to approve the COVID-19 vaccine for adolescents ages 12-17.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.